Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PSI-697 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PSI-697 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PSI-697 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: Inclusion Criteria: * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12?lead electrocardiogram (ECG). * Smoker of at least 1 pack or more of cigarettes per day (20 plus or minus...
PSI-697 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 clinical trial evaluating its effects on platelets in healthy male subjects who smoke. The program is early stage, and no approved indication has been disclosed for PSI-697.
PSI-697 is made by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 study of PSI-697 in healthy volunteers who smoke. No partner or licensing arrangement for PSI-697 has been disclosed.
PSI-697 is in Phase 1 development. Its only recorded clinical trial, NCT03860506, was a completed Phase 1 study. PSI-697 is investigational and has not been approved for any indication. No later-phase trials of PSI-697 have been registered.
PSI-697 has been studied in one clinical trial: NCT03860506, titled Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke. That Phase 1 trial enrolled 30 healthy male volunteers aged 18 years and older, was randomized, double-blind, and placebo-controlled, and is now completed.
The Phase 1 study of PSI-697, NCT03860506, was a randomized, double-blind, placebo-controlled trial in 30 healthy male volunteers who smoke, all aged 18 years or older. It evaluated the effects of PSI-697 on platelets. The trial is completed, and no active trials of PSI-697 are ongoing.